<DOC>
	<DOC>NCT02303769</DOC>
	<brief_summary>Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic</brief_summary>
	<brief_title>Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS</brief_title>
	<detailed_description>GL2702 GLARS-NF1 tablet is controlled released formation which is made by GL Pharm Tech</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Over 50 years old, BPH diagnosted, Adult Male Subject IPSS ≥ 13 point PSA &lt; 4ng/mL 5ml/sec &lt; Qmax ≤ 15ml/sec Prostatic cancer 250ml &lt; PVR ALT or AST &gt; 2 times (Upper Normal Range) Total Bilirubin &gt; 1.5 times (Upper Normal Range) Treated with αadrenalin receptor blocker within 2weeks before screening Treated with 5AlphaReductase Inhibitor within 6 months before screening Treated with phytotherapy within 2weeks before screening Treated with Anabolic Steroid within 6 months before screening</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Lower Urinary Track Syndrome</keyword>
	<keyword>Harnal</keyword>
	<keyword>Tamsulosin HCL 0.4mg</keyword>
</DOC>